Revolution Medicines, Inc. Earnings Per Share (Basic)
Revolution Medicines, Inc. (RVMD) reported Earnings Per Share (Basic) of -$3.06 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-05
- Revolution Medicines, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$3.06.
- Revolution Medicines, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$2.29.
- Revolution Medicines, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$1.88.
- Revolution Medicines, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$1.61.
- Revolution Medicines, Inc. earnings per share, basic for fiscal 2025 was -$5.95.
- Revolution Medicines, Inc. earnings per share, basic for fiscal 2024 was -$3.58.
- Revolution Medicines, Inc. earnings per share, basic for fiscal 2023 was -$3.86.
- Revolution Medicines, Inc. earnings per share, basic for fiscal 2022 was -$3.08.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.06 10-Q · filed 2026-08-05 | -$5.37 10-Q · filed 2026-08-05 | -$7.27 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$8.92 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2026-03-31 | -$2.29 10-Q · filed 2026-05-06 | -$4.17 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$5.79 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$7.12 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-12-31 | -$1.88 derived: net income ÷ weighted average shares · filed 2026-02-25 | -$3.49 derived: net income ÷ weighted average shares · filed 2026-02-25 | -$4.81 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$5.95 10-K · filed 2026-02-25 |
| 2025-09-30 | -$1.61 10-Q · filed 2025-11-05 | -$2.93 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$4.06 10-Q · filed 2025-11-05 | -$5.19 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-06-30 | -$1.31 10-Q · filed 2026-08-05 | -$2.45 10-Q · filed 2026-08-05 | -$3.57 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$4.53 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-03-31 | -$1.13 10-Q · filed 2026-05-06 | -$2.25 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$3.20 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$4.02 derived: net income ÷ weighted average shares · filed 2026-05-06 |
| 2024-12-31 | -$1.12 derived: net income ÷ weighted average shares · filed 2026-02-25 | -$2.06 derived: net income ÷ weighted average shares · filed 2026-02-25 | -$2.87 derived: net income ÷ weighted average shares · filed 2026-02-25 | -$3.58 10-K · filed 2026-02-25 |
| 2024-09-30 | -$0.94 10-Q · filed 2025-11-05 | -$1.74 derived: net income ÷ weighted average shares · filed 2025-11-05 | -$2.45 10-Q · filed 2025-11-05 | -$3.55 derived: net income ÷ weighted average shares · filed 2026-02-25 |
| 2024-06-30 | -$0.81 10-Q · filed 2025-08-06 | -$1.51 10-Q · filed 2025-08-06 | -$2.61 derived: net income ÷ weighted average shares · filed 2026-02-25 | -$3.58 derived: net income ÷ weighted average shares · filed 2026-02-25 |
| 2024-03-31 | -$0.70 10-Q · filed 2025-05-07 | -$1.81 derived: net income ÷ weighted average shares · filed 2026-02-25 | -$2.79 derived: net income ÷ weighted average shares · filed 2026-02-25 | -$3.71 derived: net income ÷ weighted average shares · filed 2026-02-25 |
| 2023-12-31 | -$1.14 derived: net income ÷ weighted average shares · filed 2026-02-25 | -$2.15 derived: net income ÷ weighted average shares · filed 2026-02-25 | -$3.09 derived: net income ÷ weighted average shares · filed 2026-02-25 | -$3.86 10-K · filed 2026-02-25 |
| 2023-09-30 | -$0.99 10-Q · filed 2024-11-06 | -$1.91 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$2.65 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$0.92 10-Q · filed 2024-08-07 | -$1.65 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | -$0.72 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$3.08 10-K · filed 2025-02-26 | |||
| 2022-09-30 | -$0.87 10-Q · filed 2023-11-06 | -$2.47 10-Q · filed 2023-11-06 | ||
| 2022-06-30 | -$0.82 10-Q · filed 2023-08-08 | -$1.60 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$0.78 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | -$0.71 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$1.43 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$2.04 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$2.57 10-K · filed 2024-02-26 |
| 2021-09-30 | -$0.72 10-Q · filed 2022-11-07 | -$1.32 derived: net income ÷ weighted average shares · filed 2022-11-07 | -$1.85 10-Q · filed 2022-11-07 | |
| 2021-06-30 | -$0.60 10-Q · filed 2022-08-09 | -$1.13 10-Q · filed 2022-08-09 | ||
| 2020-12-31 | -$2.01 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |